EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Pre-existing immunity modulates responses to mRNA boosters

Tanushree Dangi, Sarah Sanchez, Min Han Lew, Bakare Awakoaiye, Lavanya Visvabharathy, Justin M Richner, Igor J Koralnik, Pablo Penaloza-MacMaster

Cell Reports · 2023-03 · 42 (3) · 112167

DOI: 10.1016/j.celrep.2023.112167 ↗

At a glance

Journal article in Cell Reports, 2023-03. Written by Tanushree Dangi and 7 co-authors. Institution: Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. Major MEDLINE topics: BNT162 Vaccine, COVID-19. Cited 49 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIDA NIH HHS, NIAID NIH HHS, NIBIB NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

mRNA vaccines are effective in preventing severe COVID-19, but breakthrough infections, emerging variants, and waning immunity warrant the use of boosters. Although mRNA boosters are being implemented, the extent to which pre-existing immunity influences the efficacy of boosters remains unclear. In a cohort of individuals primed with the mRNA-1273 or BNT162b2 vaccines, we report that lower antibody levels before boost are associated with higher fold-increase in antibody levels after boost, suggesting that pre-existing antibody modulates the immunogenicity of mRNA vaccines. Our studies in mice show that pre-existing antibodies accelerate the clearance of vaccine antigen via Fc-dependent mechanisms, limiting the amount of antigen available to prime B cell responses after mRNA boosters. These data demonstrate a "tug of war" between pre-existing antibody responses and de novo B cell responses following mRNA vaccination, and they suggest that transient downmodulation of antibody effector function may improve the efficacy of mRNA boosters.

Subjects

MeSH terms (MEDLINE)

BNT162 VaccineCOVID-19AnimalsHumansMiceImmunization, SecondaryAntibodiesRNA, MessengermRNA VaccinesAntibodies, ViralAntibodies, Neutralizing

Author keywords

CP: ImmunologyOmicron variantSARS-CoV-2antibody effector functionsmRNA vaccinespre-existing immunityupdated vaccines

Substances

BNT162 VaccineAntibodiesRNA, MessengermRNA VaccinesAntibodies, ViralAntibodies, Neutralizing

Authors and institutions

  • Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
  • Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
  • Department of Microbiology and Immunology, University of Illinois Chicago College of Medicine, Chicago, IL 60612, USA.
  • Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. Electronic address: ppm@northwestern.edu.

Funding

  • NIDA NIH HHS
  • NIAID NIH HHS
  • NIBIB NIH HHS
  • National Institute on Drug Abuse
  • National Institute of Biomedical Imaging and Bioengineering

Cite

APA

Dangi, T., Sanchez, S., Lew, M. H., Awakoaiye, B., Visvabharathy, L., Richner, J. M., Koralnik, I. J., & Penaloza-MacMaster, P. (2023). Pre-existing immunity modulates responses to mRNA boosters. Cell Reports, 42(3), 112167. https://doi.org/10.1016/j.celrep.2023.112167

Vancouver

Dangi T, Sanchez S, Lew MH, Awakoaiye B, Visvabharathy L, Richner JM, et al. Pre-existing immunity modulates responses to mRNA boosters. Cell Reports. 2023;42(3):112167. doi:10.1016/j.celrep.2023.112167

BibTeX
@article{Dangi2023,
  author = {Dangi, Tanushree and Sanchez, Sarah and Lew, Min Han and Awakoaiye, Bakare and Visvabharathy, Lavanya and Richner, Justin M and Koralnik, Igor J and Penaloza-MacMaster, Pablo},
  title = {Pre-existing immunity modulates responses to mRNA boosters},
  journal = {Cell Reports},
  year = {2023},
  volume = {42},
  number = {3},
  pages = {112167},
  doi = {10.1016/j.celrep.2023.112167}
}
Start for free →